Welcome to our dedicated page for Ifabric news (Ticker: IFABF), a resource for investors and traders seeking the latest updates and insights on Ifabric stock.
iFabric Corp. reports developments in technology-enhanced apparel and intelligent fabrics through its wholly owned subsidiary Intelligent Fabric Technologies (North America) Inc. Company updates frequently cover medical apparel programs such as Doctor's Choice scrubs and Frontline scrubs, along with proprietary textile technologies including PROTX2 antimicrobial treatment, ecoPEL fluorine-free durable water repellent technology, and DryTX moisture management.
Recurring news also includes financial results, revenue outlooks, retailer program expansions, and new product categories that apply IFTNA technologies to performance apparel, footwear, bedding, and other finished goods. The company's public updates also reference brand and retail programs including Verzus All Apparel, Roots branded footwear, and the Coconut Grove subsidiary within iFabric's broader operating structure.
iFabric (OTCQX:IFABF) announced that subsidiary Intelligent Fabric Technologies (North America) has signed an agreement with GermstopSQ to develop, manufacture, and commercialize a new PROTX2®-based durable antimicrobial hard-surface coating. The platform is intended to provide long-lasting active antimicrobial performance on frequently touched surfaces across healthcare, hospitality, education, transportation, and other settings.
According to iFabric, Germstop will lead formulation and manufacturing, while IFTNA will handle branding, commercialization, distribution, sublicensing, and market development, initially in Canada and the United States with potential global expansion. The technology is expected to undergo efficacy testing and pursue applicable regulatory pathways in key jurisdictions.
Hylton Karon announced that on July 10, 2026 he disposed of 700,000 common shares of iFabric Corp. (TSX: IFA, IFABF) at CAD$4.50 per share, for total consideration of CAD$3,150,000, via sales to two arm's length accredited investors.
According to Hylton Karon, his holdings decreased from 17,836,350 common shares plus 200,000 options (about 49.1% on a partially diluted basis) to 17,136,350 common shares plus the same options (about 47.2%), a reduction of roughly 1.9 percentage points. The shares were sold for personal financial reasons, and he may trade further in iFabric securities subject to applicable laws.
iFabric (OTCQX:IFABF) announced that its subsidiary Intelligent Fabric Technologies (North America) is launching Aura, a new performance medical scrub line, in cooperation with a leading U.S. national mass retailer. Aura will initially roll out to approximately 400 physical stores across the United States and the retailer’s e-commerce platform.
Aura scrubs integrate IFTNA’s PROTX2 antimicrobial and ecoPEL fluorine-free water-repellent textile technologies. According to iFabric, an IFTNA-sponsored clinical trial published in the Journal of Hospital Infection showed statistically-significant reductions in bacterial contamination on treated scrubs. This is the third major retailer to adopt IFTNA’s technology-enhanced scrub platform, with collaboration extending beyond technology supply to product development, branding, manufacturing, and retail execution.
iFabric (OTCQX:IFABF, TSX:IFA) reported voting results from its June 29, 2026 annual general meeting. Approximately 20.3 million shares, or 67% of outstanding shares, were represented. All matters were approved, including electing six directors and re-appointing BDO Canada LLP as auditor.
Hylton Karon, a major shareholder of iFabric Corp (TSX: IFA, OTC: IFABF), sold 1,210,935 common shares on June 5, 2026 at $3.70 per share for total proceeds of CAD$4,480,459.50.
His partially diluted ownership decreased from 63.1% (19,047,285 shares plus 200,000 options) to 49.3% (17,836,350 shares plus 200,000 options). The shares were sold for personal financial reasons, and he may trade iFabric securities in the future subject to applicable laws.
iFabric Corp (OTCQX:IFABF) reported record Q1 2026 revenue of $27.5 million, up 288% year-over-year, and net earnings of $3.7 million ($0.122 per share) versus $88,458 a year earlier. Adjusted EBITDA rose to $5.7 million as Intelligent Fabrics and Intimate Apparel revenues more than tripled, despite a 6-point gross margin decline to 33% and higher SG&A costs.
iFabric (OTCQX:IFABF) reported record full-year 2025 revenue of $32.9M, up 20% from 2024, led by a 33% increase in its Intelligent Fabrics division to $26.2M. Gross margin fell to 32% from 41% due to tariffs and one-time brand transition costs.
Adjusted EBITDA was $1.93M for 2025. Cash rose to $3.78M and the Q1 2026 revenue outlook was raised to $25–$27M from $20–$25M.
iFabric (OTCQX:IFABF) reported estimated fiscal 2025 revenue of approximately $33 million, a 20% year-over-year increase and a new 12-month record. The company expects Q1 2026 revenue of $20–$25 million, substantially above Q1 2025's $7.1 million, driven by expanding clinically-proven scrubs programs and IFTNA category growth.
Management cites record Q4 2025 revenue of ~$11 million, targeted Q4 inventory clearance investments, and a shift from the Maidenform license to the company's own brand platform.
iFabric (OTCQX:IFABF) announced a 1,000‑store expansion of Doctor's Choice® scrubs at a leading U.S. national big‑box retailer, increasing in‑store distribution after a late 2025 rollout.
The collection integrates IFTNA technologies including PROTX2 and ecoPEL, and peer‑reviewed clinical trial results showed statistically significant reductions in surface bacterial contamination on treated scrubs.
iFabric (OTCQX:IFABF) subsidiary IFTNA launched Frontline™ antimicrobial scrubs at a major Canadian wholesale club e-commerce platform on February 18, 2026. Frontline combines IFTNA's PROTX2® antimicrobial and ecoPEL™ water-repellent technologies, validated by a peer-reviewed clinical trial showing statistically significant bacterial reductions on treated scrubs.
The launch is presented as a commercial milestone and IFTNA's second major retail adoption, highlighting its end-to-end product development and manufacturing capabilities for retail scale.